Filing Flows › Arcus Biosciences (RCUS) › Q2 2026 › vs Q2 2025
Arcus Biosciences (RCUS) Q2 2026 vs Q2 2025 (year over year)
Arcus Biosciences's revenue fell $119M (-74%) from $160M in Q2 2025 to $41.0M in Q2 2026. The biggest changes: License and development services −$136M (-89%); Other collaboration +$17.0M (+212%).
Arcus Biosciences, Q2 2026: revenue $41.0M (-74% year over year), operating margin -234.1%, net loss $91.0M, operating cash flow −$119M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Other collaboration | $25.0M | $8.0M | $17.0M | +212% |
| License and development services | $16.0M | $152M | −$136M | -89% |
| Revenue | $41.0M | $160M | −$119M | -74% |
| Other income, net | $5.0M | $8.0M | −$3.0M | -38% |
| Net loss | $91.0M | $0 | $91.0M | — |
| Costs & expenses | $137M | $168M | −$31.0M | -18% |
| Operating costs | $137M | $168M | −$31.0M | -18% |
| Research & development | $113M | $139M | −$26.0M | -19% |
| General & admin | $24.0M | $29.0M | −$5.0M | -17% |
| Operating cash sources | $137M | $150M | −$13.0M | -9% |
| Depreciation & amortization | $3.0M | $2.0M | $1.0M | +50% |
| Share-based compensation | $15.0M | $15.0M | $0 | 0% |
| Cash used in operations | $119M | $133M | −$14.0M | -11% |
| Net loss absorbed | $91.0M | $0 | $91.0M | — |
| Working capital & other | $46.0M | $150M | −$104M | -69% |
Questions
How much did Arcus Biosciences's revenue grow year over year in Q2 2026?
Arcus Biosciences's revenue fell $119M (-74%) from $160M in Q2 2025 to $41.0M in Q2 2026.
What drove Arcus Biosciences's revenue change in Q2 2026?
License and development services −$136M (-89%); Other collaboration +$17.0M (+212%).